Since TLR-4 and NF-κB activation are triggered by accumulated lyso-Gb3 in FD [49], this highlights a mechanistic link between SGLT2 inhibitors and potential disease modification in FD, making them a compelling target for further research in Fabry-related cardiomyopathy and nephropathy. This evidence concerns the gene TLR4 and Fabry disease.